Stroke is the second most common cause of death and is a major cause of permanent
disability. Given the current demographic trend of an ageing population and associated …

In order to study the molecular pathways of Parkinson's disease (PD) and to develop novel
therapeutic strategies, scientific investigators rely on animal models. The identification of PD …

The development of in vivo imaging protocols to reliably track transplanted cells or to report
on gene expression is critical for treatment monitoring in (pre) clinical cell and gene therapy …

Endogenous neural stem cells have the potential to facilitate therapy for various
neurodegenerative brain disorders. To increase our understanding of neural stem and …

State-of-the-art small-animal single photon emission computed tomography (SPECT)
enables sub-half-mm resolution imaging of radio-labelled molecules. Due to severe photon …

The interest in the use of stem cells as a source for therapy has increased dramatically over
the last decades. Different stem cell types have been tested in both in vitro and in vivo …

Alpha-synuclein (αSYN) aggregation plays a pivotal role in the pathogenesis of Parkinson's
disease and other synucleinopathies. In this multistep process, oligomerization of αSYN …

The type 2 cannabinoid receptor (CB2R) is a relatively new target for drug development, as
the receptor was only discovered in 1993. The CB2R is mainly expressed in tissues and …

As the interest in gene therapy increases, the development of an efficient and reliable
means to monitor gene delivery and expression in patients is becoming more important. An …

Integral to the development of all gene therapy technologies is the ability to monitor gene
delivery, in terms of distribution, levels and kinetics of vector transgene expression. This can …